Today: 30 April 2026
Browse Category

NASDAQ:INTS 30 October 2025 - 31 October 2025

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Shares of Intensity Therapeutics closed at $1.32 on Oct. 30, surging nearly 395% intraday after Phase 1/2 trial data for INT230-6 showed a 75% disease-control rate in metastatic cancer. Over a billion shares traded, dwarfing the usual volume. After-hours, the price fell to around $0.90. The company’s market cap remains under $65 million.
31 October 2025
··
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Intensity Therapeutics shares surged nearly 200% on Oct. 30, 2025, after Phase 1/2 trial results for INT230-6 showed a 75% disease control rate and median survival of 11.9 months in advanced cancer patients. The stock traded around $0.27 with a market cap near $13.1 million and daily volume spiking to 279 million shares. INT230-6 is in late-stage trials for sarcoma and breast cancer.
30 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 30.10.2025

US stocks fell Oct. 30, with the S&P 500 down 0.99% and Nasdaq off 1.57%. Oracle shares dropped 6.8% to $256.28 despite analysts raising price targets and maintaining buy ratings. Liberty Latin America slid about 6% in a month, closing near $7.77, well below its $10.63 fair value estimate. Intensity Therapeutics surged nearly 400%, while CERO plunged almost 95%.
30 October 2025
·······

Stock Market Today

  • Eaton (ETN) Share Price Gains vs Valuation: Is It Overvalued?
    April 29, 2026, 7:54 PM EDT. Eaton (ETN) shares have surged 41.3% over the past year, driven by its role in capital goods and electrical equipment sectors amid rising infrastructure interest. The stock closed at $410.77, up 25.5% year-to-date but down 0.7% over the past week. Despite robust returns, Eaton scored 2/6 on valuation checks. A Discounted Cash Flow (DCF) analysis projects intrinsic value at $283.53 per share, suggesting a 44.9% overvaluation relative to current prices. The DCF model uses projected free cash flows growing from $3.6 billion to $10.9 billion by 2035, discounted to present value. Investors should weigh Eaton's strong market position against stretched valuations, considering other metrics like price-to-earnings ratios to assess reasonable entry points.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Go toTop